TM Owner Biogen
Spinraza 12mg/5ml Injection
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Spinraza (nusinersen sodium) 12 mg/5 mL is an antisense oligonucleotide that increases production of full-length SMN protein by modifying splicing of the SMN2 gene.
- It is approved in the US and EU for the treatment of 5q spinal muscular atrophy (SMA) in patients of any age, from infants to adults, across all SMA types.
- It is given only by a specialist, usually a neurologist, as an intrathecal injection directly into the fluid around the spinal cord - it must never be given intravenously or by any other route.
- After 4 loading doses over the first two months, maintenance doses continue once every 4 months for the duration of treatment; there is no home or self-administered version, and Biogen supplies Spinraza under this single global brand name in both the US and EU.
Side Effects
- Common effects reported vary by SMA type and dose but include fever, headache, vomiting, back pain, and, in infants, lower respiratory infections and constipation.
- No boxed warning appears on the current US or EU label; however, Spinraza's label carries important warnings for thrombocytopenia (low platelets, including severe drops) and coagulation abnormalities that can increase bleeding risk, and for renal toxicity seen as increased protein in the urine.
- Report unusual bruising or bleeding, blood in urine or stool, reduced urine output, or swelling promptly.
- Because it is given by lumbar puncture, some people get a post-procedure headache or back pain, or, rarely, signs of meningitis-like irritation such as fever and neck stiffness - tell your care team immediately if these occur.
Precautions & Warnings
- Before every dose, blood tests for platelet count and coagulation, plus a urine protein test, are required, since Spinraza can cause thrombocytopenia, clotting problems and kidney protein loss; abnormal results may delay or adjust a dose.
- Ultrasound-guided lumbar puncture may be needed in patients with spinal deformity, rods, or after spinal surgery.
- Spinraza is given only in a clinic or hospital setting by trained staff - there is no missed-dose or home-storage concern for patients, since the treating centre manages both scheduling and the drug's refrigerated cold-chain storage.
- Safety in pregnancy and breastfeeding has not been established; discuss family planning with your neurologist if relevant.
- Dosing is age-based rather than restricted by a lower age limit.
Avoid Interactions
- No specific drug-drug interaction studies have been conducted with Spinraza, and it is not expected to interact through liver enzyme pathways.
- Because it can lower platelet counts and affect clotting, tell your care team about any other medicines that increase bleeding risk, such as anticoagulants (warfarin, direct oral anticoagulants) or antiplatelet drugs (aspirin, clopidogrel), as extra monitoring may be needed around dosing and lumbar puncture.
- There are no known food interactions.
- Always tell the treating team about every medicine, herbal product and supplement used, since the pre-dose blood and urine tests help catch any effect on clotting or kidney function early.
References
Frequently Asked Questions
Spinraza (nusinersen) treats 5q spinal muscular atrophy (SMA), a genetic disease that weakens muscles, in patients of any age from infants to adults. It works by helping cells make more of the SMN protein motor neurons need. It's used across all SMA types, not just infant-onset disease.
Spinraza is injected directly into the fluid around your spinal cord by a specialist, never into a vein or muscle. After 4 loading doses in the first two months, maintenance doses are given once every 4 months, for as long as treatment continues, always in a clinic or hospital.
Common Spinraza side effects include fever, headache, vomiting, back pain, and post-procedure headache from the spinal injection. Spinraza can also lower platelets and affect blood clotting, and can cause kidney protein loss, so report unusual bruising, bleeding, or reduced urination straight away.
Before every Spinraza dose, you need blood tests to check platelets and clotting, plus a urine test for protein, because the drug can affect blood clotting and kidney function. Your neurologist may delay or adjust a dose if these results are abnormal.
A specialist gives Spinraza by lumbar puncture, the same technique used for a spinal tap, often with ultrasound guidance. You may feel a brief sting, and some people get a headache or back soreness afterward that usually settles within a day or two.
Yes. Spinraza (nusinersen) is approved for 5q SMA at any age, from newborns to adults, and across all SMA types, including infant-onset, later-onset, and adult-onset disease. Dosing follows a fixed schedule rather than body weight after the loading doses, and treatment usually continues long-term.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
